As the global burden of thromboembolic disorders continues to rise—with
over 900,000 pulmonary embolism cases reported annually in the U.S. alone—the demand for a reliable Urokinase Manufacturer has become
increasingly critical for hospitals, pharmaceutical distributors, and healthcare
providers worldwide. Urokinase, a serine protease that efficiently activates
plasminogen to dissolve fibrin clots, is a life-saving
thrombolytic agent used to treat deep vein thrombosis, pulmonary embolism, and
catheter occlusion, with its market projected to reach USD 780.75 million by
2035. Kangyuan, a pioneering Urokinase Manufacturer with over
two decades of expertise, stands out by integrating innovative production
technology, strict quality control, and global regulatory compliance, delivering
high-purity urokinase tailored to the diverse needs of North America, Europe,
Asia-Pacific, and emerging economies.
What distinguishes Kangyuan as a leading Urokinase Manufacturer is its
proprietary production process that addresses industry challenges of yield,
purity, and bioactivity. Unlike conventional manufacturers struggling with
misfolded proteins and low active yields, Kangyuan adopts an
advanced purification technology combining D160 cationic resin exchange,
affinity membrane chromatography, and affinity chromatography,
ensuring our urokinase achieves a specific activity of over 150,000 IU/mg·pr and
a polymer content exceeding 96%. We source raw materials from a standardized
collection network, collecting approximately 50 tons of qualified male urine
daily, and utilize a controlled extraction process to
preserve the enzyme’s native 411-amino-acid structure and multiple disulfide
bonds, critical for its thrombolytic efficacy.
As a global Urokinase Manufacturer, Kangyuan excels in navigating complex
regional regulatory frameworks, a key advantage for partners seeking seamless
market access. In Europe, our urokinase complies with strict EMA guidelines,
which emphasize rigorous purification processes to remove viral impurities and
ensure safety, supporting its adoption in hospitals across the
EU. In North America, we meet FDA standards, aligning with the region’s high
demand for reliable thrombolytics to address the 895,241 annual venous
thromboembolism cases. In Asia-Pacific, the fastest-growing
market for urokinase, we leverage our status as China’s first
and only enterprise passing FDA inspection for urinary-derived APIs, offering cost-effective solutions that balance quality with regional
healthcare budgets.
Kangyuan’s competitive edge as a Urokinase Manufacturer lies in its
scalable capacity, comprehensive quality assurance, and customer-centric
service. Our GMP-certified facilities (Certificate No. SD20160456)boast a monthly production capacity of approximately 15,000 MIU, capable of fulfilling both small-batch R&D orders and
large-scale commercial supply. Every batch undergoes rigorous testing, including
potency validation, sterility checks, and impurity screening, ensuring
compliance with USP, EP, and ChP standards. We also offer flexible formulations,
including lyophilized powder and injectable solutions, tailored to regional
clinical preferences, and provide full regulatory support—including DMF filings
and COAs—to accelerate market entry for our partners.
As the global urokinase market grows at a CAGR of 4.08% through 2035, driven by rising cardiovascular disease rates and expanding
emergency care capacity, Kangyuan remains at the forefront of innovation. Our
ongoing R&D focuses on enhancing urokinase stability and reducing bleeding
risks, aligning with industry trends toward safer, more
efficient thrombolytics. Backed by decades of expertise and a commitment to
quality, Kangyuan has become a trusted Urokinase Manufacturer for businesses in
50+ countries.
Ready to partner with a reliable Urokinase Manufacturer? Contact Kangyuan
today to discuss your specific requirements, request samples, or learn how our
advanced thrombolytic solutions can elevate your products and help you gain a
competitive edge in your regional market.